Barclays Maintains Overweight on LifeStance Health Gr, Raises Price Target to $15
Barclays analyst Peter Warendorf maintains LifeStance Health Gr (NASDAQ:LFST) with a Overweight and raises the price target from $13 to $15.
Stocks · News reference
8-K filing — LifeStance Health Group, Inc. (LFST)
Filed: 2026-09-11 AccNo: 0001193125-26-389315 Size: 424 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Canaccord Genuity Maintains Buy on LifeStance Health Gr, Raises Price Target to $15
Canaccord Genuity analyst Richard Close maintains LifeStance Health Gr (NASDAQ:LFST) with a Buy and raises the price target from $13 to $15.
LifeStance Prices 22.25M Share Secondary Offering At $12.35/Share; Co To Repurchase 2M Shares